Holen Sie sich die Stockscreener-App
1.22
10.91%
0.12
Handel nachbörslich:
1.22
Schlusskurs vom Vortag:
$1.10
Offen:
$1.38
24-Stunden-Volumen:
44.34M
Relative Volume:
5.56
Marktkapitalisierung:
$89.64M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-22.83M
KGV:
-1.5443
EPS:
-0.79
Netto-Cashflow:
$-20.87M
1W Leistung:
+71.59%
1M Leistung:
+115.02%
6M Leistung:
+106.78%
1J Leistung:
+106.78%
1-Tages-Spanne:
$1.15
$1.47
1-Wochen-Bereich:
$0.6012
$1.47
52-Wochen-Spanne:
$0.2223
$1.47
Cognition Therapeutics Inc Stock (CGTX) Company Profile
Firmenname
Cognition Therapeutics Inc
Sektor
Branche
Telefon
412-481-2210
Adresse
2403 SIDNEY STREET, PITTSBURGH
Vergleichen Sie CGTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CGTX
Cognition Therapeutics Inc
|
1.22 | 80.82M | 0 | -22.83M | -20.87M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-19 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2024-07-30 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-11-03 | Eingeleitet | B. Riley Securities | Buy |
| 2021-11-03 | Eingeleitet | Oppenheimer | Outperform |
Cognition Therapeutics Inc Aktie (CGTX) Neueste Nachrichten
CGTX Stock Surge: Deciphering the Spike - StocksToTrade
Cognition Therapeutics stock jumps after FDA confirms Phase 3 design By Investing.com - Investing.com Nigeria
Is CGTX Stock About to Skyrocket? - timothysykes.com
CGTX Soars 34.55% on FDA Phase 3 Trial Endorsement - AInvest
Cognition Therapeutics Inc. (CGTX) Soars 25.45% on FDA Trial Endorsement - AInvest
Cognition Therapeutics Surges 30% Pre-Market After FDA Backs Phase 3 Trial Design For Alzheimer's Drug - Benzinga
Regulatory Clarity and Accelerated Path to Commercialization: Cognition Therapeutics' Strategic Position in Alzheimer's Therapeutics - AInvest
Cognition Therapeutics Receives End-of-Phase 2 Meeting - GlobeNewswire
Cognition Therapeutics aligns with FDA on Alzheimer’s drug phase 3 design - Investing.com
Breakthrough Alzheimer's Drug Zervimesine Advances to Phase 3 with Novel Blood Test Strategy - Stock Titan
Cognition Therapeutics (CGTX) Surges 19.88%: What’s Fueling This Biotech Breakout? - AInvest
Alzheimer's disease Clinical Trials, Companies, Therapeutic - openPR.com
Alzheimer’s disease Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | AriBio Co., Ltd., Eli Lilly & Co., Cognition Therapeutics, AbbVie Inc., Allyx Therape - Barchart.com
Cognition Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Cognition Therapeutics reports Q2 EPS (11c), consensus (10c) - TipRanks
Cognition Therapeutics Reports Q2 2025 Results, Highlights Clinical Progress - AInvest
Cognition Therapeutics: Pivotal Alzheimer's Milestones and Strategic Pathways to Value Creation in 2025 - AInvest
Cognition Therapeutics Reports Financial Results for the - GlobeNewswire
Breakthrough Alzheimer's Drug Shows 28% Success Rate as Cognition Advances Multiple Clinical Programs - Stock Titan
Published on: 2025-08-05 16:54:31 - beatles.ru
Top Risks to Consider Before Buying Cognition Therapeutics Inc. StockWeekly Chart Analysis With Entry Advice Provided - metal.it
Is Cognition Therapeutics Inc. a good long term investmentCapitalize on momentum-driven stocks - Jammu Links News
What are the latest earnings results for Cognition Therapeutics Inc.Invest confidently with real-time updates - Jammu Links News
What catalysts could drive Cognition Therapeutics Inc. stock higher in 2025Superior profit margins - Jammu Links News
What makes Cognition Therapeutics Inc. stock price move sharplyMaximize returns with disciplined trading approaches - Jammu Links News
Is it the right time to buy Cognition Therapeutics Inc. stockTriple-digit returns - Jammu Links News
Why is Cognition Therapeutics Inc. stock attracting strong analyst attentionFree Daily Trading Room Entry - Jammu Links News
How volatile is Cognition Therapeutics Inc. stock compared to the marketBreakthrough capital growth - Jammu Links News
What analysts say about Cognition Therapeutics Inc. stockDynamic growth stocks - Jammu Links News
What institutional investors are buying Cognition Therapeutics Inc. stockAchieve rapid returns with smart investment plans - jammulinksnews.com
Does Cognition Therapeutics Inc. stock perform well during market downturnsGet exclusive access to premium stock research - Jammu Links News
Cognition Therapeutics’ Expanded Access Program for CT1812: A Promising Update for Investors - The Globe and Mail
Is Cognition Therapeutics Inc. a growth stock or a value stockValue Investing Entry Points With Proven Results - Jammu Links News
What are analysts’ price targets for Cognition Therapeutics Inc. in the next 12 monthsPost Market Recommendation With High Returns - Jammu Links News
Cognition Therapeutics’ drug shows 129% cognitive decline arrest in mild Alzheimer’s - Yahoo Finance
Published on: 2025-07-29 20:05:06 - metal.it
Applying sector rotation models to Cognition Therapeutics Inc.Long Hold Safe Return Strategy Reviewed - metal.it
New Data: Zervimesine for the Treatment of Dementia With Lewy Bodies and Alzheimer Disease - Psychiatric Times
How high can Cognition Therapeutics Inc. stock price go in 2025Conservative Long Term Growth Plans Under Review - metal.it
Cognition Therapeutics Presents Data at AAIC Highlighting - GlobeNewswire
Breakthrough Drug Zervimesine Halts Alzheimer's Decline by 129%, Shows Promise in Lewy Body Dementia - Stock Titan
Cognition Therapeutics shares rise 3.50% premarket after PTC Therapeutics' FDA approval of Sephience. - AInvest
Finanzdaten der Cognition Therapeutics Inc-Aktie (CGTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):